PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
11739621-7	2001	Cell surface DAT binding ([3H]WIN 35,428; 4 nM) also increased as a function of ethanol exposure time.	Tritium	27-29	solute carrier family 6 member 3	Homo sapiens	13-16	
12064476-11	2002	In keeping with the increase in DAT function, [3H]WIN 35,428 binding was increased in the cocaine users, but not in the victims of excited delirium.	Tritium	47-49	solute carrier family 6 member 3	Homo sapiens	32-35	
11820798-1	2002	In HEK 293 cells expressing the human dopamine transporter (DAT), a 10-min incubation with 10 microM cocaine followed by extensive washing resulted in a 30% increase in [3H]dopamine (DA) uptake as well as an increase in cell surface DAT in biotinylation experiments.	Tritium	170-172	solute carrier family 6 member 3	Homo sapiens	38-58	
11820798-1	2002	In HEK 293 cells expressing the human dopamine transporter (DAT), a 10-min incubation with 10 microM cocaine followed by extensive washing resulted in a 30% increase in [3H]dopamine (DA) uptake as well as an increase in cell surface DAT in biotinylation experiments.	Tritium	170-172	solute carrier family 6 member 3	Homo sapiens	60-63	
11160629-6	2001	The affinity of DA for the DAT, as measured by [3H]DA uptake experiments, was higher in both the cryopreserved human caudate and freshly prepared rat striatum than in HEK-hDAT cells.	Tritium	48-50	solute carrier family 6 member 3	Homo sapiens	27-30	
11431013-2	2001	The radiolabeled DAT ligand [3H]GBR12935 was bound to peripheral lymphocytes in a manner consistent with the specific binding to a dopamine uptake system, with a dissociation constant similar to that found in striatum, but with a lower density of binding sites.	Tritium	29-31	solute carrier family 6 member 3	Homo sapiens	17-20	
10737611-2	2000	In this study, substrate recognition was studied via the inhibition of binding of [3H]WIN 35,428 [2beta-carbomethoxy-3beta-(4-fluorophenyl)[3H]tropane], a cocaine analogue, to the human dopamine transporter in human embryonic kidney 293 cells.	Tritium	83-85	solute carrier family 6 member 3	Homo sapiens	186-206	
9325175-5	1997	Engineered Sfn insect cells infected with a recombinant baculovirus bearing the human dopamine transporter gene under the control of the polyhedrin promoter showed a > or = 5 times enhanced uptake of [3H]dopamine in comparison to similarly infected Sf9 cells.	Tritium	204-206	solute carrier family 6 member 3	Homo sapiens	86-106	
10371159-2	1999	In kidney-derived COS-7, COS-1 and HEK-293 but not in other mammalian cell lines (CHO, Y1, Ltk-), we have characterized a putative functional dopamine transporter displaying a high affinity (Km approximately 250 nM) and a low capacity (approximately 0.1 pmol/10(5) cells/min) for [3H]dopamine uptake.	Tritium	281-283	solute carrier family 6 member 3	Homo sapiens	142-162	
10215666-5	1999	The potency of drugs at blocking [3H]neurotransmitter uptake was highly correlated with potency at blocking radioligand binding for hDAT and hSERT.	Tritium	34-36	solute carrier family 6 member 3	Homo sapiens	132-136	
10037481-0	1999	Modeling of the interaction of Na+ and K+ with the binding of dopamine and [3H]WIN 35,428 to the human dopamine transporter.	Tritium	76-78	solute carrier family 6 member 3	Homo sapiens	103-123	
10037481-2	1999	This was addressed here by studying the inhibition by dopamine of the binding of [3H]WIN 35,428 [2beta-carbomethoxy-3beta-(4-fluorophenyl)[3H]tropane], a phenyltropane analogue of cocaine, to the cloned human dopamine transporter expressed in HEK-293 cells.	Tritium	82-84	solute carrier family 6 member 3	Homo sapiens	209-229	
10330690-5	1999	DAT levels were measured by [3H]-WIN 35,428 autoradiography, and dopamine content decreased with increasing MPTP dose.	Tritium	29-31	solute carrier family 6 member 3	Homo sapiens	0-3	
9989560-3	1999	METHOD: In the present study, binding of the cocaine analog [3H]WIN 35428 to the dopamine transporter was assayed in postmortem striatal samples from 15 cocaine-using subjects and 15 matched comparison subjects to determine whether there were differences in number of binding sites or in affinity.	Tritium	61-63	solute carrier family 6 member 3	Homo sapiens	81-101	
9664843-6	1998	These mode matches successfully predicted the nonlinear kinetic interactions of NT-(DA)D2 in contrast with CCK-(DA) D2 on 3H-spiperone binding to (DA) D2, and by CCK-DAT but not NT-DAT on [N-methyl-3H]-WIN 35,428 binding to DAT in (DA)D2 and DAT cDNA stably transfected cell lines without known NT or CCK receptors.	Tritium	122-124	solute carrier family 6 member 3	Homo sapiens	181-184	
9664843-6	1998	These mode matches successfully predicted the nonlinear kinetic interactions of NT-(DA)D2 in contrast with CCK-(DA) D2 on 3H-spiperone binding to (DA) D2, and by CCK-DAT but not NT-DAT on [N-methyl-3H]-WIN 35,428 binding to DAT in (DA)D2 and DAT cDNA stably transfected cell lines without known NT or CCK receptors.	Tritium	122-124	solute carrier family 6 member 3	Homo sapiens	181-184	
9664843-6	1998	These mode matches successfully predicted the nonlinear kinetic interactions of NT-(DA)D2 in contrast with CCK-(DA) D2 on 3H-spiperone binding to (DA) D2, and by CCK-DAT but not NT-DAT on [N-methyl-3H]-WIN 35,428 binding to DAT in (DA)D2 and DAT cDNA stably transfected cell lines without known NT or CCK receptors.	Tritium	122-124	solute carrier family 6 member 3	Homo sapiens	181-184	
9466707-0	1997	Dopamine transporter development in postnatal rat striatum: an autoradiographic study with [3H]WIN 35,428.	Tritium	92-94	solute carrier family 6 member 3	Homo sapiens	0-20	
9466707-3	1997	[3H]WIN 35,428 is a cocaine analog that is useful for studying the distribution and density of the dopamine transporter in striatum and other brain regions.	Tritium	1-3	solute carrier family 6 member 3	Homo sapiens	99-119	
9466707-4	1997	The postnatal development of the dopamine transporter in the rat striatum was measured by quantitative autoradiography with [3H]WIN 35,428.	Tritium	125-127	solute carrier family 6 member 3	Homo sapiens	33-53	
10685879-6	2000	The inhibitory effect on [3H]DA uptake was reversible and not dependent on pH, as observed in HeLa cells stably expressing DAT.	Tritium	26-28	solute carrier family 6 member 3	Homo sapiens	123-126	
9704884-3	1998	As with both native neuronal and cloned DATs, acute exposure of hDAT expressing Sf9 cells to the PKC activator PMA (1 microM), but not alphaPDD, reduced the Vmax (approximately 1 pmol/min/10(5) cells) for [3H]DA uptake by approximately 40%, an effect which was blocked by the protein kinase inhibitor staurosporine.	Tritium	206-208	solute carrier family 6 member 3	Homo sapiens	64-68	
9704884-8	1998	Immunofluorescent confocal microscopy demonstrated that the observed functional consequence of PKC activation on [3H]DA uptake is associated with the rapid sequestration/internalization of hDAT protein from the cell surface, while the increase in DA uptake following PKC/PKA inhibition is the result of the recruitment of internalized or intracellular transporters to the plasma membrane.	Tritium	114-116	solute carrier family 6 member 3	Homo sapiens	189-193	
9729282-1	1998	Human cocaine users exhibit increased striatal [3H]WIN35428 binding to the dopamine transporter (DAT).	Tritium	48-50	solute carrier family 6 member 3	Homo sapiens	75-95	
9729282-1	1998	Human cocaine users exhibit increased striatal [3H]WIN35428 binding to the dopamine transporter (DAT).	Tritium	48-50	solute carrier family 6 member 3	Homo sapiens	97-100	
9435903-5	1997	Importantly, the analogue 16, with the highest affinity for the dopamine transporter (DAT), binds in a monophasic and irreversible manner, as evidenced by the greatly diminished binding of [3H]WIN 35,428 in tissue that had been preincubated with the ligand and then thoroughly washed using centrifugation.	Tritium	190-192	solute carrier family 6 member 3	Homo sapiens	64-84	
9435903-5	1997	Importantly, the analogue 16, with the highest affinity for the dopamine transporter (DAT), binds in a monophasic and irreversible manner, as evidenced by the greatly diminished binding of [3H]WIN 35,428 in tissue that had been preincubated with the ligand and then thoroughly washed using centrifugation.	Tritium	190-192	solute carrier family 6 member 3	Homo sapiens	86-89	
9435903-7	1997	This shift in KD to a lower value suggests that the preincubation with 16 produced a preferential irreversible binding to the low-affinity [3H]WIN 35,428 site on the dopamine transporter.	Tritium	140-142	solute carrier family 6 member 3	Homo sapiens	166-186	
9282933-0	1997	Cations affect [3H]mazindol and [3H]WIN 35,428 binding to the human dopamine transporter in a similar fashion.	Tritium	16-18	solute carrier family 6 member 3	Homo sapiens	68-88	
9316847-2	1997	When Xenopus oocytes expressing the cloned human dopamine transporter (hDAT) were pretreated with bath-applied phorbol 12-myristate 13-acetate (PMA), a PKC activator, [3H]DA uptake decreased irreversibly in a time- and dose-dependent manner (IC50 = 22 nM; maximal inhibition = 63-85%).	Tritium	168-170	solute carrier family 6 member 3	Homo sapiens	49-69	
9282933-0	1997	Cations affect [3H]mazindol and [3H]WIN 35,428 binding to the human dopamine transporter in a similar fashion.	Tritium	33-35	solute carrier family 6 member 3	Homo sapiens	68-88	
8937455-0	1996	Binding domains for blockers and substrates on the cloned human dopamine transporter studied by protection against N-ethylmaleimide-induced reduction of 2 beta-carbomethoxy-3 beta-(4-fluorophenyl)[3H]tropane ([3H]WIN 35,428) binding.	Tritium	197-199	solute carrier family 6 member 3	Homo sapiens	64-84	
9262359-2	1997	In the present study, we address this issue by examining the inhibition by mazindol of the binding of [3H]WIN 35,428 ([3H]2beta-carbomethyoxy-3beta-(4-fluorophenyl)-tropane), a phenyltropane analog of cocaine, and the inhibition by WIN 35,428 of [3H]mazindol binding to the cloned human dopamine transporter expressed in C6 glioma cells.	Tritium	103-105	solute carrier family 6 member 3	Homo sapiens	287-307	
9154329-4	1997	In DAT cells lowering the Na+ concentration to 0, 5 or 10 mM caused an increase in 3H-efflux.	Tritium	83-85	solute carrier family 6 member 3	Homo sapiens	3-6	
9154329-13	1997	In cross-loading experiments, 5 mM Na(+)- or 0 Cl(-)-induced efflux was much lower from [3H]-noradrenaline-loaded DAT, than NAT cells and was sensitive to mazindol, but not to desipramine.	Tritium	89-91	solute carrier family 6 member 3	Homo sapiens	114-117	
9258354-5	1997	The binding affinities of these compounds were determined at the dopamine transporter for the displacement of [3H]WIN-35428.	Tritium	111-113	solute carrier family 6 member 3	Homo sapiens	65-85	
9109912-2	1997	To determine whether the DA reduction was accompanied by loss of DA nerve terminals, we measured levels of the DA transporter ([3H]WIN, 35,428 binding; DA transporter protein) and the vesicular monoamine transporter ([3H]DTBZ binding) in the putamen of these patients.	Tritium	128-130	solute carrier family 6 member 3	Homo sapiens	111-125	
9113087-4	1997	The reduction in dopamine transporter activity by PMA was caused by a decrease in the Vmax value of [3H]dopamine uptake, opposed by a smaller reduction in the Km value, whereas the effect of PMA on [3H]WIN 35,428 binding was caused by a reduction in the Bmax value without a change in the Kd value.	Tritium	101-103	solute carrier family 6 member 3	Homo sapiens	17-37	
9113087-4	1997	The reduction in dopamine transporter activity by PMA was caused by a decrease in the Vmax value of [3H]dopamine uptake, opposed by a smaller reduction in the Km value, whereas the effect of PMA on [3H]WIN 35,428 binding was caused by a reduction in the Bmax value without a change in the Kd value.	Tritium	199-201	solute carrier family 6 member 3	Homo sapiens	17-37	
9135047-3	1997	Unilateral intranigral administration of dopamine transporter antisense (50 microM) twice daily in freely moving rats for 2.5 days was sufficient to reduce dopamine transporter messenger RNA by 70% as measured by in situ hybridization, but not protein levels as measured by [3H]mazindol binding.	Tritium	275-277	solute carrier family 6 member 3	Homo sapiens	41-61	
8723710-4	1996	D-Amphetamine, which releases DA from neurons and blocks the DA transporter directly, inhibited striatal [3H]WIN 35,428 binding in dose-dependent manner.	Tritium	106-108	solute carrier family 6 member 3	Homo sapiens	61-75	
8797470-2	1996	These markers included DA itself, three different estimates of the density of the DA transporter (DAT) ([3H])GBR 12,935 and [3H]WIN 35,428 binding; DAT protein immunoreactivity), and one estimate of the vesicular monoamine transporter (VMAT2; [3H]DTBZ binding).	Tritium	105-107	solute carrier family 6 member 3	Homo sapiens	82-96	
8797470-2	1996	These markers included DA itself, three different estimates of the density of the DA transporter (DAT) ([3H])GBR 12,935 and [3H]WIN 35,428 binding; DAT protein immunoreactivity), and one estimate of the vesicular monoamine transporter (VMAT2; [3H]DTBZ binding).	Tritium	105-107	solute carrier family 6 member 3	Homo sapiens	98-101	
8702845-2	1996	In order to delineate structural motifs regulating substrate affinity and recognition for the human dopamine transporter (DAT), we assessed [3H]dopamine uptake kinetics and [3H]CFT binding characteristics of COS-7 cells transiently expressing mutant DATs in which the COOH terminus was truncated or substituted.	Tritium	141-143	solute carrier family 6 member 3	Homo sapiens	100-120	
8702845-2	1996	In order to delineate structural motifs regulating substrate affinity and recognition for the human dopamine transporter (DAT), we assessed [3H]dopamine uptake kinetics and [3H]CFT binding characteristics of COS-7 cells transiently expressing mutant DATs in which the COOH terminus was truncated or substituted.	Tritium	141-143	solute carrier family 6 member 3	Homo sapiens	122-125	
8702845-2	1996	In order to delineate structural motifs regulating substrate affinity and recognition for the human dopamine transporter (DAT), we assessed [3H]dopamine uptake kinetics and [3H]CFT binding characteristics of COS-7 cells transiently expressing mutant DATs in which the COOH terminus was truncated or substituted.	Tritium	174-176	solute carrier family 6 member 3	Homo sapiens	100-120	
8702845-2	1996	In order to delineate structural motifs regulating substrate affinity and recognition for the human dopamine transporter (DAT), we assessed [3H]dopamine uptake kinetics and [3H]CFT binding characteristics of COS-7 cells transiently expressing mutant DATs in which the COOH terminus was truncated or substituted.	Tritium	174-176	solute carrier family 6 member 3	Homo sapiens	122-125	
8702845-3	1996	Complete truncation of the carboxyl tail from Ser582 allowed for the expression of biphasic [3H]dopamine uptake kinetics displaying both a low capacity (Vmax approximately 0.4 pmol/10(5) cells/min) high affinity (Km approximately 300 nM) component and one exhibiting low affinity (Km approximately 15 microM] and high capacity (Vmax approximately 5 pmol/10(5)cells/min) with a concomitant 40% decrease in overall apparent Vmax relative to wild type (WT) DAT.	Tritium	93-95	solute carrier family 6 member 3	Homo sapiens	454-457	
8702845-7	1996	In marked contrast, DAT truncation/substitution mutants displayed significantly reduced high affinity [3H]CFT binding interactions with estimated Ki values for dopamine and numerous other substrates and inhibitors tested from 10-100-fold lower than that observed for WT DAT.	Tritium	103-105	solute carrier family 6 member 3	Homo sapiens	20-23	
8702845-7	1996	In marked contrast, DAT truncation/substitution mutants displayed significantly reduced high affinity [3H]CFT binding interactions with estimated Ki values for dopamine and numerous other substrates and inhibitors tested from 10-100-fold lower than that observed for WT DAT.	Tritium	103-105	solute carrier family 6 member 3	Homo sapiens	270-273	
8843076-8	1996	Likewise, transient transfection of NMB cells with the plasmid expressing dopamine transporter complementary DNA in the antisense orientation partially blocked [3H]dopamine uptake.	Tritium	161-163	solute carrier family 6 member 3	Homo sapiens	74-94	
8302271-0	1994	Pharmacological heterogeneity of the cloned and native human dopamine transporter: disassociation of [3H]WIN 35,428 and [3H]GBR 12,935 binding.	Tritium	102-104	solute carrier family 6 member 3	Homo sapiens	61-81	
7996484-4	1994	The potent cocaine congener [3H]WIN 35,428 ((CFT), 2B-carbomethoxy-3 beta-(4-fluorophenyl)-tropane) has been shown to recognize high and low affinity binding sites on the DA transporter.	Tritium	29-31	solute carrier family 6 member 3	Homo sapiens	171-185	
7996484-5	1994	We have used [3H]WIN 35,428 to map and quantify the high affinity cocaine recognition site on the DA transporter in victims of fatal cocaine overdose.	Tritium	14-16	solute carrier family 6 member 3	Homo sapiens	98-112	
7851480-4	1994	In in vitro binding assays all three dl-threo bromo compounds had higher affinities than methylphenidate for dopamine transporter sites labeled with [3H]2 beta-carbomethoxy-3 beta-(4-fluorophenyl)tropane ([3H]WIN 35,428; IC50 = 13, 4, 20 and 82 nM for o-, m-, and p-bromo compounds, and unsubstituted methylphenidate, respectively).	Tritium	150-152	solute carrier family 6 member 3	Homo sapiens	109-129	
7851480-4	1994	In in vitro binding assays all three dl-threo bromo compounds had higher affinities than methylphenidate for dopamine transporter sites labeled with [3H]2 beta-carbomethoxy-3 beta-(4-fluorophenyl)tropane ([3H]WIN 35,428; IC50 = 13, 4, 20 and 82 nM for o-, m-, and p-bromo compounds, and unsubstituted methylphenidate, respectively).	Tritium	206-208	solute carrier family 6 member 3	Homo sapiens	109-129	
8180805-4	1994	The decreases in [3H]GBR-12935 binding to DA uptake sites in this study indicate a marked degeneration of DA neurites in the putamen in PD and also in DAT.	Tritium	18-20	solute carrier family 6 member 3	Homo sapiens	151-154	
8302271-0	1994	Pharmacological heterogeneity of the cloned and native human dopamine transporter: disassociation of [3H]WIN 35,428 and [3H]GBR 12,935 binding.	Tritium	121-123	solute carrier family 6 member 3	Homo sapiens	61-81	
8302271-4	1994	[3H]DA uptake was inhibited in a concentration-dependent and uniphasic manner by dopaminergic agents with an appropriate rank order of potency for the DA transporter.	Tritium	1-3	solute carrier family 6 member 3	Homo sapiens	151-165	
8302271-10	1994	Taken together, these data suggest that 1) [3H]WIN 35,428 recognizes two sites of the DA transporter, of which only one appears to represent the functional state of the protein, and 2) [3H]WIN 35,428 and [3H]GBR 12,935 do not appear to bind the same functional form/state of the DA transporter.	Tritium	44-46	solute carrier family 6 member 3	Homo sapiens	86-100	
8302271-10	1994	Taken together, these data suggest that 1) [3H]WIN 35,428 recognizes two sites of the DA transporter, of which only one appears to represent the functional state of the protein, and 2) [3H]WIN 35,428 and [3H]GBR 12,935 do not appear to bind the same functional form/state of the DA transporter.	Tritium	44-46	solute carrier family 6 member 3	Homo sapiens	279-293	
1987318-5	1991	The asymmetrical loss of the dopamine transporter in Parkinson"s diseased striatum was confirmed in reversible receptor binding experiments using [3H]GBR-12935 (3H-labeled 1-[2-(diphenylmethoxy) ethyl]-4-(3-phenylpropyl)piperazine).	Tritium	147-149	solute carrier family 6 member 3	Homo sapiens	29-49	
1796351-1	1991	The cocaine congener [3H]CFT, also designated [3H]WIN 35,428 (2 beta-carbomethoxy-3 beta-(4-fluorophenyltropane), labels cocaine receptors associated with the dopamine transporter in primate striatum.	Tritium	22-24	solute carrier family 6 member 3	Homo sapiens	159-179	
1796351-1	1991	The cocaine congener [3H]CFT, also designated [3H]WIN 35,428 (2 beta-carbomethoxy-3 beta-(4-fluorophenyltropane), labels cocaine receptors associated with the dopamine transporter in primate striatum.	Tritium	47-49	solute carrier family 6 member 3	Homo sapiens	159-179	
1987318-5	1991	The asymmetrical loss of the dopamine transporter in Parkinson"s diseased striatum was confirmed in reversible receptor binding experiments using [3H]GBR-12935 (3H-labeled 1-[2-(diphenylmethoxy) ethyl]-4-(3-phenylpropyl)piperazine).	Tritium	161-163	solute carrier family 6 member 3	Homo sapiens	29-49	
6667712-0	1983	Decrease in [3H]cocaine binding to the dopamine transporter in Parkinson"s disease.	Tritium	13-15	solute carrier family 6 member 3	Homo sapiens	39-59	
2120386-7	1990	Pharmacological characterization suggests that [3H]WIN 35,065-2 binds to the dopamine transporter.	Tritium	48-50	solute carrier family 6 member 3	Homo sapiens	77-97	
34195432-4	2021	The inhibition constant (Ki) for l-menthol inhibition of binding of (3H)-WIN35,428 to the human recombinant dopamine transporter was 6.15 x 10-4 mol/L.	Tritium	69-71	solute carrier family 6 member 3	Homo sapiens	108-128	
2812250-7	1989	Nicotinic binding measured with [3H]ACh, but not (-)-[3H]Nic, was significantly lower in the H2 (field of Rose) and H1-subiculum areas of DAT samples compared to control.	Tritium	33-35	solute carrier family 6 member 3	Homo sapiens	138-141	
3598589-0	1987	[3H]GBR-12935 binding to the dopamine transporter is decreased in the caudate nucleus in Parkinson"s disease.	Tritium	1-3	solute carrier family 6 member 3	Homo sapiens	29-49	
28859474-10	2017	The binding of a dopamine reuptake inhibitor, [3H]-WIN35,428, to DAT is significantly disrupted by aggregated-7-(10,10)CNTs and hence improve the ability to transport dopamine.	Tritium	47-49	solute carrier family 6 member 3	Homo sapiens	65-68	
29414147-5	2018	RESULTS: In SH-SY5Y cells, [3H]-dopamine uptake was inhibited by desipramine (selective NET inhibitor), GBR-12909 (selective DAT inhibitor), and fluoxetine (selective inhibitor of the serotonin transporter, SERT) with IC50 values 37, 537, and 2800nM, respectively.	Tritium	28-30	solute carrier family 6 member 3	Homo sapiens	125-128	
33537927-3	2021	Compared to wild-type hDAT, the maximal velocity (Vmax) of [3H]dopamine uptake was decreased in D381L and Y88F/D206L/H547A, increased in D206L/H547A, and unaltered in D206L.	Tritium	60-62	solute carrier family 6 member 3	Homo sapiens	22-26	
33537927-5	2021	Mutational effects of hDAT on the transporter conformation were evidenced by attenuation of zinc-induced increased [3H]WIN35,428 binding in D206L/H547A and Y88F/D206A/H547A and enhanced basal MPP+ efflux in D206L/H547A.	Tritium	116-118	solute carrier family 6 member 3	Homo sapiens	22-26	
30284596-13	2019	Repeated doses of MDPV developed tolerance to this DAT upregulation and 24 h after the 5-day treatment with MDPV, [3H]DA uptake was reduced.	Tritium	115-117	solute carrier family 6 member 3	Homo sapiens	51-54	
28031054-5	2017	The DAT was measured by means of the [3H]-WIN 35,428 binding and the [3H]-DA reuptake to resting lymphocytes membranes.	Tritium	38-40	solute carrier family 6 member 3	Homo sapiens	4-7	
28824395-6	2017	Radioligand binding assays of [3H]WIN35,428 demonstrated that the number of striatal DAT binding sites was inversely correlated with increasing BMI (r = -0.47; p < 0.01).	Tritium	31-33	solute carrier family 6 member 3	Homo sapiens	85-88	
28031054-5	2017	The DAT was measured by means of the [3H]-WIN 35,428 binding and the [3H]-DA reuptake to resting lymphocytes membranes.	Tritium	70-72	solute carrier family 6 member 3	Homo sapiens	4-7	
19910055-1	2010	The aim of our study was to investigate and compare the dopamine (DA) transporter (DAT) in resting lymphocytes of 20 psychotic patients and 20 healthy control subjects, by means of both the binding parameters (Bmax and Kd) of 3H-WIN 35,428, and the reuptake parameters (Vmax and Km) of 3H-DA.	Tritium	226-228	solute carrier family 6 member 3	Homo sapiens	83-86	
26305376-4	2015	Co-expression of DAT and DJ-1 in HEK-293T cells leads to an increase in [3H] dopamine uptake that does not appear to be mediated by increased total DAT expression but rather through an increase in DAT cell surface localization.	Tritium	73-75	solute carrier family 6 member 3	Homo sapiens	17-20	
26305376-7	2015	Co-expression of a mini-gene that can disrupt the DAT/DJ-1 complex appears to block the increase in [3H] dopamine uptake by DJ-1.	Tritium	101-103	solute carrier family 6 member 3	Homo sapiens	50-53	
25772534-2	2015	In a study by Zhen and colleagues highlighted by this Editorial in the current issue of Journal of Neurochemistry, the combination of mutant and wild-type dopamine transporter (DAT) has been used to establish the cooperation between transporter protomers; the DAT mutant version has an altered affinity for the radiolabelled inhibitor [3H]CFT.	Tritium	336-338	solute carrier family 6 member 3	Homo sapiens	155-175	
25772534-2	2015	In a study by Zhen and colleagues highlighted by this Editorial in the current issue of Journal of Neurochemistry, the combination of mutant and wild-type dopamine transporter (DAT) has been used to establish the cooperation between transporter protomers; the DAT mutant version has an altered affinity for the radiolabelled inhibitor [3H]CFT.	Tritium	336-338	solute carrier family 6 member 3	Homo sapiens	177-180	
25772534-2	2015	In a study by Zhen and colleagues highlighted by this Editorial in the current issue of Journal of Neurochemistry, the combination of mutant and wild-type dopamine transporter (DAT) has been used to establish the cooperation between transporter protomers; the DAT mutant version has an altered affinity for the radiolabelled inhibitor [3H]CFT.	Tritium	336-338	solute carrier family 6 member 3	Homo sapiens	260-263	
25580950-4	2015	In this work, human embryonic kidney 293 cells were co-transfected with DAT constructs possessing differential binding affinities for the phenyltropane cocaine analog, [3H]WIN35,428.	Tritium	169-171	solute carrier family 6 member 3	Homo sapiens	72-75	
19098122-8	2009	For T62A-hDAT, however, the measured 50% reduction in both [(3)H]dopamine uptake and [(3)H]dopamine efflux was consistent with a slowed transition between inward- and outward-facing conformations.	Tritium	61-64	solute carrier family 6 member 3	Homo sapiens	9-13	
19628755-8	2009	Instead, roscovitine enhanced spontaneous [3H]DA outflow and inhibited DAT-mediated [3H]DA reaccumulation into dSTR slices.	Tritium	85-87	solute carrier family 6 member 3	Homo sapiens	71-74	
16309561-5	2005	RESULTS: [3H] Win 35,428 saturation binding assays and DAT immunoblots revealed statistically significant differences in DAT expression attributable to DAT1 genotype.	Tritium	10-12	solute carrier family 6 member 3	Homo sapiens	121-124	
17625500-8	2008	Post-mortem analysis of METH brains showed 20% lower striatal DA content while autoradiography studies of precommissural striatum showed 35% lower [3H]WIN35428 binding to the DA transporter.	Tritium	148-150	solute carrier family 6 member 3	Homo sapiens	175-189	
16220332-4	2007	METHODS: We investigated the interaction of [(3)H](+/-, RS)- (+, S)- and (-, R)-MDMA with the human SERT, dopamine (DA) transporter (DAT), and norepinephrine (NE) transporter (NET) in stably transfected human embryo kidney (HEK)-293 cells.	Tritium	44-49	solute carrier family 6 member 3	Homo sapiens	133-136	
16712814-5	2006	In an extension of our previous work, the current study, using receptor autoradiography, compared binding (by [3H]WIN35428) of the dopamine transporter (DAT) in animals having experienced either brief or extended daily access to cocaine over 8 days, followed by 14 days of withdrawal.	Tritium	111-113	solute carrier family 6 member 3	Homo sapiens	131-151	
16712814-5	2006	In an extension of our previous work, the current study, using receptor autoradiography, compared binding (by [3H]WIN35428) of the dopamine transporter (DAT) in animals having experienced either brief or extended daily access to cocaine over 8 days, followed by 14 days of withdrawal.	Tritium	111-113	solute carrier family 6 member 3	Homo sapiens	153-156	
18038207-1	2008	The paucity of information on the presence of the dopamine transporter (DAT) in blood cells, prompted us to explore it in human resting lymphocytes by means of the binding of 3H-WIN 35,428, a compound which is currently considered the most selective ligand for labelling this protein, and by means of the specific reuptake of 3H-dopamine (3H-DA).	Tritium	175-177	solute carrier family 6 member 3	Homo sapiens	50-70	
18038207-1	2008	The paucity of information on the presence of the dopamine transporter (DAT) in blood cells, prompted us to explore it in human resting lymphocytes by means of the binding of 3H-WIN 35,428, a compound which is currently considered the most selective ligand for labelling this protein, and by means of the specific reuptake of 3H-dopamine (3H-DA).	Tritium	175-177	solute carrier family 6 member 3	Homo sapiens	72-75	
17510552-5	2007	METHODS: Tegaserod inhibition of SERT-mediated [3H]5-HT and NET- and DAT-mediated [3H]dopamine uptake was measured in human embryonic kidney (HEK) 293 cells stably expressing hSERT, hDAT, and hNET in comparison with untransfected control HEK293-FT cells.	Tritium	83-85	solute carrier family 6 member 3	Homo sapiens	69-72	
16309561-5	2005	RESULTS: [3H] Win 35,428 saturation binding assays and DAT immunoblots revealed statistically significant differences in DAT expression attributable to DAT1 genotype.	Tritium	10-12	solute carrier family 6 member 3	Homo sapiens	152-156	
12837768-4	2003	Of 18 mutations where hNET amino acid residues were exchanged with those of the human dopamine transporter, MrIA had increased potency for inhibition of [3H]norepinephrine uptake for three mutations (in predicted extracellular loops 3 and 4 and transmembrane domain (TMD) 8) and decreased potency for one mutation (in TMD6 and intracellular loop (IL) 3).	Tritium	154-156	solute carrier family 6 member 3	Homo sapiens	86-106	
15102929-5	2004	High concentrations of lobeline induced a statistically significant release of [3H]DA from HEK-hDAT-hVMAT2 cells, but only in the absence of DHTB, suggesting an hVMAT2-mediated effect.	Tritium	80-82	solute carrier family 6 member 3	Homo sapiens	95-99	
15102929-2	2004	Cofunction of hDAT and hVMAT2 caused greater retention of [3H]DA at 20 min (37 degrees C), or 45 min (22 degrees C) compared with cells that were treated with dihydrotetrabenazene (DHTB) to block the hVMAT2.	Tritium	59-61	solute carrier family 6 member 3	Homo sapiens	14-18	
12727318-3	2003	Saturation binding studies using [3H]mazindol showed a high affinity DAT binding site with K(D) and B(max) values of 12.32+/-1.67 nM and 82.7+/-9.74 fmol/mg protein, respectively.	Tritium	34-36	solute carrier family 6 member 3	Homo sapiens	69-72